Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;96(1):e29317.
doi: 10.1002/jmv.29317.

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

Marta Sisteré-Oró  1 , Juan Du  2 , Diana D J Wortmann  1 , Marina D Filippi  1 , Esperanza Cañas-Ruano  2 , Itziar Arrieta-Aldea  2 , Agustín Marcos-Blanco  2 , Xavier Castells  3 , Santiago Grau  4 , Natalia García-Giralt  2   5 , Daniel Perez-Zsolt  6 , Rytis Boreika  6 , Nuria Izquierdo-Useros  6   7   8 , Robert Güerri-Fernandez  2   8   9 , Andreas Meyerhans  1   10
Affiliations

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

Marta Sisteré-Oró et al. J Med Virol. 2024 Jan.

Abstract

People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm3 blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations.

Keywords: HIV-1-infected individuals; JYNNEOS vaccination; monkeypox (mpox); pan-pox-specific T-cell responses.

PubMed Disclaimer

References

REFERENCES

    1. Hernaez B, Muñoz-Gómez A, Sanchiz A, et al. Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study. Lancet Microbe. 2023;4(1):e21-e28. doi:10.1016/s2666-5247(22)00291-9
    1. Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun. 2022;131:102855. doi:10.1016/j.jaut.2022.102855
    1. Kozlov M. Monkeypox goes global: why scientists are on alert. Nature. 2022;606(7912):15-16. doi:10.1038/d41586-022-01421-8
    1. Grifoni A, Zhang Y, Tarke A, et al. Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. Cell Host Microbe. 2022;30(12):1662-1670. doi:10.1016/j.chom.2022.11.003
    1. World Health Organization. Vaccines and immunization for Monkeypox. Published June 14, 2022. Accessed August 11 2023; https://apps.who.int/iris/bitstream/handle/10665/356120/WHO-MPX-Immuniza...

Publication types